agmatine has been researched along with Disease Models, Animal in 74 studies
Agmatine: Decarboxylated arginine, isolated from several plant and animal sources, e.g., pollen, ergot, herring sperm, octopus muscle.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to demonstrate the activity of agmatine, an inducible nitric oxide synthase (iNOS) inhibitor and selective N-methyl-D-aspartate receptor (NMDAR) antagonist, on reducing tissue damage in distal part of traumatic nerve in an experimental rat peripheral nerve injury model." | 9.19 | Neuroprotective effects of agmatine in experimental peripheral nerve injury in rats: a prospective randomized and placebo-controlled trial. ( Cakir, M; Coban, MK; Guclu, B; Kazanci, B; Sezer, A, 2014) |
| "In the current study, we investigate whether oral administration of agmatine (AGM) could effectively reduce motor and cognitive deficits induced by bile duct ligation (BDL) in an animal model of hepatic encephalopathy (HE) through neuroprotective mechanisms." | 8.31 | Agmatine improves liver function, balance performance, and neuronal damage in a hepatic encephalopathy induced by bile duct ligation. ( Asadi-Shekaari, M; Asadikaram, G; Ganjalikhan-Hakemi, S; Nozari, M; Pourjafari, F, 2023) |
| " This study evaluates the effects of agmatine on ovalbumin (OVA)-induced allergic inflammation of the airways." | 8.12 | Effect of Agmatine on a mouse model of allergic airway inflammation: A comparative study. ( Abdelaziz, RR; Elmahdi, HS; Suddek, GM; Еlmahdy, MK, 2022) |
| "The effect of agmatine in preclinical behavioral tests of schizophrenia has been examined in rodents." | 7.78 | Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. ( Chopde, CT; Gawande, DY; Hadole, PN; Kotagale, NR; Mendhi, SM; Palhade, MW; Taksande, BG; Wadhwani, PJ, 2012) |
| "To examine the protective effects of agmatine (AGM) administration on zymosan (ZYM)-induced inflammatory response and acute lung injury (ALI) in mice." | 7.77 | [The protective effects of agmatine in zymosan induced acute lung injury in mice]. ( Bao, YX; Fan, X; Gu, Y; Liang, HP; Yang, X; Zhang, C, 2011) |
| " Similar to lithium, agmatine plays a protective role in the central nervous system against seizures and has been reported to enhance the effect of different antiepileptic agents." | 7.76 | Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: Involvement of L-arginine/nitric oxide pathway. ( Bahremand, A; Dehpour, AR; Ghasemi, A; Ghasemi, M; Hedayat, T; Khodadad, TK; Payandemehr, B; Rahimian, R; Ziai, P, 2010) |
| "The present study examined the anti-hypernociceptive effects of agmatine (AGM) in acute and chronic models of behavioural pain in mice." | 7.74 | Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. ( Calixto, JB; Gadotti, VM; Paszcuk, AF; Quintão, NL; Rodrigues, AL; Santos, AR; Tibola, D, 2007) |
| "Intraspinal injection of the AMPA/metabotropic receptor agonist quisqualic acid (QUIS) results in a pathophysiology that leads to excessive grooming behavior, which has been proposed as a model of spontaneous at-level pain after spinal cord injury (SCI)." | 7.72 | Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. ( Fairbanks, CA; Wilcox, GL; Yezierski, RP; Yu, CG, 2003) |
| "To study the antimalarial effect of agmatine (Agm) on chloroquine-susceptible Plasmodium berghei K173 strain (S strain) and the P berghei K173 resistant strain (R strain)." | 7.72 | Antimalarial effect of agmatine on Plasmodium berghei K173 strain. ( Li, J; Liu, Y; Su, RB; Wei, XL, 2003) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 5.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "Agmatine accumulation was a direct result of mutations in aguA, encoding the arginine deiminase that catalyses the conversion of agmatine into various polyamines." | 5.51 | Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation. ( Evert, C; Gilbertsen, AJ; Hunter, RC; McCurtain, JL; Williams, BJ, 2019) |
| "The mechanical allodynia, thermal hyperalgesia [corrected], and tail clip tests were performed, and DRG cells and sciatic nerves were analyzed." | 5.48 | Agmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in rats. ( Aydin, S; Cengelli Unel, C; Donertas, B; Erol, K; Kaygisiz, B; Ozatik, O; Ulupinar, E; Yildirim, E, 2018) |
| "Agmatine has been reported to attenuate I/R injury of various organs." | 5.46 | Agmatine attenuates intestinal ischemia and reperfusion injury by reducing oxidative stress and inflammatory reaction in rats. ( Araslı, M; Barut, F; Ozacmak, HS; Ozacmak, VH; Turan, I, 2017) |
| ") injection of agmatine (1mg/kg) for 30 min increased the plasma beta-endorphin-like immunoreactivity (BER) in a way parallel to the reduction of plasma glucose in sham-operated fructose chow-fed rats; this action of agmatine was totally abolished by BU224 at sufficient dosage (1mg/kg, i." | 5.35 | Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats. ( Cheng, JT; Chung, HH; Liu, IM; Su, CH, 2009) |
| "Agmatine pre-treatment significantly reduced the seizure grade and increased the onset time." | 5.33 | Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. ( Feng, Y; LeBlanc, MH; Regunathan, S, 2005) |
| "The purpose of this study was to demonstrate the activity of agmatine, an inducible nitric oxide synthase (iNOS) inhibitor and selective N-methyl-D-aspartate receptor (NMDAR) antagonist, on reducing tissue damage in distal part of traumatic nerve in an experimental rat peripheral nerve injury model." | 5.19 | Neuroprotective effects of agmatine in experimental peripheral nerve injury in rats: a prospective randomized and placebo-controlled trial. ( Cakir, M; Coban, MK; Guclu, B; Kazanci, B; Sezer, A, 2014) |
| "In the current study, we investigate whether oral administration of agmatine (AGM) could effectively reduce motor and cognitive deficits induced by bile duct ligation (BDL) in an animal model of hepatic encephalopathy (HE) through neuroprotective mechanisms." | 4.31 | Agmatine improves liver function, balance performance, and neuronal damage in a hepatic encephalopathy induced by bile duct ligation. ( Asadi-Shekaari, M; Asadikaram, G; Ganjalikhan-Hakemi, S; Nozari, M; Pourjafari, F, 2023) |
| " This study evaluates the effects of agmatine on ovalbumin (OVA)-induced allergic inflammation of the airways." | 4.12 | Effect of Agmatine on a mouse model of allergic airway inflammation: A comparative study. ( Abdelaziz, RR; Elmahdi, HS; Suddek, GM; Еlmahdy, MK, 2022) |
| "The effect of agmatine in preclinical behavioral tests of schizophrenia has been examined in rodents." | 3.78 | Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. ( Chopde, CT; Gawande, DY; Hadole, PN; Kotagale, NR; Mendhi, SM; Palhade, MW; Taksande, BG; Wadhwani, PJ, 2012) |
| " This study investigated the effect of the interaction of melatonin and agmatine on seizure susceptibility in the mouse model of pentylenetetrazole (PTZ)-induced clonic seizures." | 3.77 | The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice. ( Dehpour, AR; Hojati, A; Moezi, L; Shafaroodi, H, 2011) |
| "To examine the protective effects of agmatine (AGM) administration on zymosan (ZYM)-induced inflammatory response and acute lung injury (ALI) in mice." | 3.77 | [The protective effects of agmatine in zymosan induced acute lung injury in mice]. ( Bao, YX; Fan, X; Gu, Y; Liang, HP; Yang, X; Zhang, C, 2011) |
| " Similar to lithium, agmatine plays a protective role in the central nervous system against seizures and has been reported to enhance the effect of different antiepileptic agents." | 3.76 | Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: Involvement of L-arginine/nitric oxide pathway. ( Bahremand, A; Dehpour, AR; Ghasemi, A; Ghasemi, M; Hedayat, T; Khodadad, TK; Payandemehr, B; Rahimian, R; Ziai, P, 2010) |
| "Agmatine, an endogenous ligand of imidazoline receptors, was employed to screen the effect on insulin resistance in rats induced by a diet containing 60% fructose." | 3.74 | Activation of I(2)-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats. ( Cheng, JT; Chung, HH; Ko, WC; Liu, IM, 2008) |
| "The present study examined the anti-hypernociceptive effects of agmatine (AGM) in acute and chronic models of behavioural pain in mice." | 3.74 | Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. ( Calixto, JB; Gadotti, VM; Paszcuk, AF; Quintão, NL; Rodrigues, AL; Santos, AR; Tibola, D, 2007) |
| "Putrescine, a polyamine present at high concentrations in the mammalian brain, was suggested to play a role in the modulation of depression." | 3.73 | Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. ( Rodrigues, AL; Santos, AR; Zomkowski, AD, 2006) |
| "Intraspinal injection of the AMPA/metabotropic receptor agonist quisqualic acid (QUIS) results in a pathophysiology that leads to excessive grooming behavior, which has been proposed as a model of spontaneous at-level pain after spinal cord injury (SCI)." | 3.72 | Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. ( Fairbanks, CA; Wilcox, GL; Yezierski, RP; Yu, CG, 2003) |
| "To study the antimalarial effect of agmatine (Agm) on chloroquine-susceptible Plasmodium berghei K173 strain (S strain) and the P berghei K173 resistant strain (R strain)." | 3.72 | Antimalarial effect of agmatine on Plasmodium berghei K173 strain. ( Li, J; Liu, Y; Su, RB; Wei, XL, 2003) |
| "Agmatine is an endogenous neuromodulator with emotional- and cognitive-enhancing properties that arises as a promising agent to manage several Central Nervous System disorders." | 1.72 | Agmatine improves olfactory and cognitive deficits in Spontaneously Hypertensive Rats (SHR): An animal model of Attention Deficit Hyperactivity Disorder (ADHD). ( Corrêa, T; da Silva-Santos, JE; de Souza, BS; França, AP; Izídio, GS; Prediger, RD; Schamne, MG, 2022) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 1.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "Agmatine accumulation was a direct result of mutations in aguA, encoding the arginine deiminase that catalyses the conversion of agmatine into various polyamines." | 1.51 | Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation. ( Evert, C; Gilbertsen, AJ; Hunter, RC; McCurtain, JL; Williams, BJ, 2019) |
| "Agmatine was injected intraperitoneally at 50 and 100 mg/kg body weight, 1 h prior to ROT administration." | 1.51 | Neuroprotective effect of agmatine (decarboxylated l-arginine) against oxidative stress and neuroinflammation in rotenone model of Parkinson's disease. ( Ahmed, A; El-Sayed, EK; Morsy, EE; Nofal, S, 2019) |
| "Depression is one of the most common psychiatric symptoms in Alzheimer's disease (AD), and several studies have shown that oxidative stress plays a key role in the etiopathology of both AD and depression." | 1.48 | Agmatine attenuates depressive-like behavior and hippocampal oxidative stress following amyloid β (Aβ1-40) administration in mice. ( de Souza, V; Farina, M; Gonçalves, CL; Guerra de Souza, AC; Hartwig, JM; Prediger, RD, 2018) |
| "The mechanical allodynia, thermal hyperalgesia [corrected], and tail clip tests were performed, and DRG cells and sciatic nerves were analyzed." | 1.48 | Agmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in rats. ( Aydin, S; Cengelli Unel, C; Donertas, B; Erol, K; Kaygisiz, B; Ozatik, O; Ulupinar, E; Yildirim, E, 2018) |
| "Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals." | 1.48 | Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone. ( Azevedo, DP; Brocardo, PS; Fraga, DB; Gil-Mohapel, J; Melleu, FF; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB, 2018) |
| "Agmatine has been reported to attenuate I/R injury of various organs." | 1.46 | Agmatine attenuates intestinal ischemia and reperfusion injury by reducing oxidative stress and inflammatory reaction in rats. ( Araslı, M; Barut, F; Ozacmak, HS; Ozacmak, VH; Turan, I, 2017) |
| "Agmatine was given before and two consecutive days after cisplatin injection." | 1.43 | Evaluation of the protective effect of agmatine against cisplatin nephrotoxicity with 99mTc-DMSA renal scintigraphy and cystatin-C. ( Aras, M; Cabuk, M; Can, M; Elri, T; Gulle, K; Ozacmak, HS; Salihoglu, YS, 2016) |
| "Agmatine is an endogenous arginine metabolite that emerges as neuromodulator and a promising agent to manage diverse central nervous system disorders by modulating nitric oxide (NO) pathway, glutamate NMDA receptors and oxidative stress." | 1.43 | Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. ( Blum-Silva, CH; Colle, D; Cunha, AS; Cunha, MP; Farina, M; Matheus, FC; Moretti, M; Poli, A; Prediger, RD; Reginatto, FH; Rodrigues, AL; Sampaio, TB; Sandjo, LP; Santos, DB, 2016) |
| "Agmatine has been reported to attenuate BBB disruption." | 1.42 | Effects of agmatine on blood-brain barrier stabilization assessed by permeability MRI in a rat model of transient cerebral ischemia. ( Ahn, KJ; Ahn, SS; Choi, HS; Kim, DJ; Kim, J; Kim, SH; Lee, JE; Lee, SK; Shin, NY, 2015) |
| "Agmatine (Agm) has been shown to exert neuroprotective effects in central nervous system disorders." | 1.40 | Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. ( Bokara, KK; Cho, HJ; Hur, BE; Lee, JE; Lee, KM; Lee, WT; Park, KA; Song, J; Yang, W, 2014) |
| "Pretreatment with yohimbine (2mg/kg, i." | 1.37 | Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation. ( Cowan, A; Hirsch, DD; Kim, J; Lisek, R; Rawls, SM; Raymondi, N; Rosenthal, A, 2011) |
| "Agmatine has been reported to exert neuroprotective effect in various stress models including central nervous system injuries." | 1.37 | Agmatine-reduced collagen scar area accompanied with surface righting reflex recovery after complete transection spinal cord injury. ( Kim, JH; Lee, JE; Lee, WT; Lee, YW; Park, KA; Park, SH; Park, YM, 2011) |
| ") injection of agmatine (1mg/kg) for 30 min increased the plasma beta-endorphin-like immunoreactivity (BER) in a way parallel to the reduction of plasma glucose in sham-operated fructose chow-fed rats; this action of agmatine was totally abolished by BU224 at sufficient dosage (1mg/kg, i." | 1.35 | Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats. ( Cheng, JT; Chung, HH; Liu, IM; Su, CH, 2009) |
| " After acquisition of intravenous morphine self-administration, chronic administration of agmatine (40 or 80 mg/kg x 30 days, bid, i." | 1.35 | Agmatine blocks acquisition and re-acquisition of intravenous morphine self-administration in rats. ( Li, J; Liu, ZM; Lu, XQ; Su, RB; Wang, WP; Wu, N, 2009) |
| "Agmatine pre-treatment significantly reduced the seizure grade and increased the onset time." | 1.33 | Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. ( Feng, Y; LeBlanc, MH; Regunathan, S, 2005) |
| "No definitive treatment for spinal cord injuries (SCIs) exists, and more research is required." | 1.33 | Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial. ( Akçetin, M; Bilge, T; Kirali, M; Kotil, K; Kuscuoglu, U; Uzun, H, 2006) |
| "Agmatine is a primary amine formed by the decarboxylation of L-arginine synthesized in mammalian brain." | 1.32 | Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. ( Cho, SW; Giffard, RG; Kim, JH; Lee, JE; Park, KA; Yenari, MA, 2004) |
| "Agmatine has recently gained wide interest as a bioactive arginine metabolite with a multitude of physiological functions." | 1.32 | Agmatine modulates the in vivo biosynthesis and interconversion of polyamines and cell proliferation. ( Colombatto, S; Dudkowska, M; Gardini, G; Grzelakowska-Sztabert, B; Lai, J; Manteuffel-Cymborowska, M; Stachurska, A, 2003) |
| "Agmatine is a naturally occurring guanidino compound, found in bacteria and plants, with several proposed nervous system-related functions suggestive of beneficial effects in central nervous system injury." | 1.29 | Agmatine treatment is neuroprotective in rodent brain injury models. ( Gilad, GM; Gilad, VH; Rabey, JM; Salame, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.35) | 18.2507 |
| 2000's | 26 (35.14) | 29.6817 |
| 2010's | 36 (48.65) | 24.3611 |
| 2020's | 11 (14.86) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Wiśniewska, A | 1 |
| Stachowicz, A | 1 |
| Kuś, K | 1 |
| Ulatowska-Białas, M | 1 |
| Totoń-Żurańska, J | 1 |
| Kiepura, A | 1 |
| Stachyra, K | 1 |
| Suski, M | 1 |
| Gajda, M | 1 |
| Jawień, J | 1 |
| Olszanecki, R | 1 |
| França, AP | 1 |
| Schamne, MG | 1 |
| de Souza, BS | 1 |
| Corrêa, T | 1 |
| da Silva-Santos, JE | 1 |
| Izídio, GS | 1 |
| Prediger, RD | 4 |
| Еlmahdy, MK | 1 |
| Abdelaziz, RR | 1 |
| Elmahdi, HS | 1 |
| Suddek, GM | 1 |
| Jeon, SJ | 1 |
| Kwon, H | 1 |
| Bae, HJ | 1 |
| Gonzales, EL | 1 |
| Kim, J | 4 |
| Chung, HJ | 1 |
| Kim, DH | 1 |
| Ryu, JH | 1 |
| Shin, CY | 2 |
| Ganjalikhan-Hakemi, S | 1 |
| Asadi-Shekaari, M | 1 |
| Pourjafari, F | 1 |
| Asadikaram, G | 1 |
| Nozari, M | 1 |
| Sahin Ozkartal, C | 1 |
| Tuzun, E | 1 |
| Kucukali, CI | 1 |
| Ulusoy, C | 1 |
| Giris, M | 1 |
| Aricioglu, F | 2 |
| Kotagale, N | 2 |
| Deshmukh, R | 1 |
| Dixit, M | 2 |
| Fating, R | 1 |
| Umekar, M | 2 |
| Taksande, B | 2 |
| Bilge, SS | 1 |
| Günaydin, C | 1 |
| Önger, ME | 1 |
| Bozkurt, A | 1 |
| Avci, B | 1 |
| Rahmatkar, S | 1 |
| Chauragade, S | 1 |
| Chopde, C | 1 |
| Sugiura, T | 1 |
| Hirasawa, Y | 1 |
| Toyoshi, T | 1 |
| Matsumura, Y | 1 |
| Akman, Ö | 1 |
| Utkan, T | 1 |
| Güllü, K | 1 |
| Ateş, N | 1 |
| Karson, A | 1 |
| El-Awady, MS | 1 |
| Nader, MA | 1 |
| Sharawy, MH | 2 |
| Olescowicz, G | 1 |
| Neis, VB | 2 |
| Fraga, DB | 1 |
| Rosa, PB | 1 |
| Azevedo, DP | 1 |
| Melleu, FF | 1 |
| Brocardo, PS | 1 |
| Gil-Mohapel, J | 1 |
| Rodrigues, ALS | 1 |
| Turan, I | 1 |
| Ozacmak, HS | 2 |
| Ozacmak, VH | 1 |
| Barut, F | 1 |
| Araslı, M | 1 |
| Bahremand, T | 1 |
| Payandemehr, P | 1 |
| Riazi, K | 1 |
| Noorian, AR | 1 |
| Payandemehr, B | 2 |
| Sharifzadeh, M | 1 |
| Dehpour, AR | 3 |
| Donertas, B | 1 |
| Cengelli Unel, C | 1 |
| Aydin, S | 1 |
| Ulupinar, E | 1 |
| Ozatik, O | 1 |
| Kaygisiz, B | 1 |
| Yildirim, E | 1 |
| Erol, K | 1 |
| Guerra de Souza, AC | 1 |
| Gonçalves, CL | 1 |
| de Souza, V | 1 |
| Hartwig, JM | 1 |
| Farina, M | 2 |
| El-Sayed, EK | 1 |
| Ahmed, A | 1 |
| Morsy, EE | 1 |
| Nofal, S | 1 |
| Selakovic, V | 1 |
| Arsenijevic, L | 1 |
| Jovanovic, M | 1 |
| Sivcev, S | 1 |
| Jovanovic, N | 1 |
| Leontijevic, M | 1 |
| Stojanovic, M | 1 |
| Radenkovic, M | 1 |
| Andjus, P | 1 |
| Radenovic, L | 1 |
| McCurtain, JL | 1 |
| Gilbertsen, AJ | 2 |
| Evert, C | 1 |
| Williams, BJ | 2 |
| Hunter, RC | 1 |
| Ramani, D | 1 |
| De Bandt, JP | 1 |
| Cynober, L | 1 |
| Manosso, LM | 1 |
| Moretti, M | 2 |
| Freitas, AE | 1 |
| Daufenbach, J | 1 |
| Rodrigues, AL | 6 |
| El-Agamy, DS | 1 |
| Ammar, EM | 1 |
| Song, J | 1 |
| Hur, BE | 1 |
| Bokara, KK | 1 |
| Yang, W | 1 |
| Cho, HJ | 1 |
| Park, KA | 4 |
| Lee, WT | 3 |
| Lee, KM | 1 |
| Lee, JE | 7 |
| Sezer, A | 1 |
| Guclu, B | 1 |
| Kazanci, B | 1 |
| Cakir, M | 1 |
| Coban, MK | 1 |
| Ahn, SS | 1 |
| Kim, SH | 1 |
| Ahn, KJ | 1 |
| Kim, DJ | 2 |
| Choi, HS | 1 |
| Shin, NY | 1 |
| Lee, SK | 2 |
| Paulson, NB | 1 |
| Dalluge, JJ | 1 |
| Welchlin, CW | 1 |
| Hughes, J | 1 |
| Han, W | 1 |
| Blackwell, TS | 1 |
| Laguna, TA | 1 |
| Kim, JM | 1 |
| Cheon, SY | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Kam, EH | 1 |
| Koo, BN | 1 |
| Donalisio, M | 1 |
| Quaranta, P | 1 |
| Chiuppesi, F | 1 |
| Pistello, M | 1 |
| Cagno, V | 1 |
| Cavalli, R | 1 |
| Volante, M | 1 |
| Bugatti, A | 1 |
| Rusnati, M | 1 |
| Ranucci, E | 1 |
| Ferruti, P | 1 |
| Lembo, D | 1 |
| Cunha, AS | 1 |
| Matheus, FC | 2 |
| Sampaio, TB | 1 |
| Poli, A | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Cunha, MP | 1 |
| Blum-Silva, CH | 1 |
| Sandjo, LP | 1 |
| Reginatto, FH | 1 |
| Salihoglu, YS | 1 |
| Elri, T | 1 |
| Gulle, K | 1 |
| Can, M | 1 |
| Aras, M | 1 |
| Cabuk, M | 1 |
| Kim, JW | 1 |
| Seung, H | 1 |
| Kim, KC | 1 |
| Gonzales, ELT | 1 |
| Oh, HA | 1 |
| Yang, SM | 1 |
| Ko, MJ | 1 |
| Han, SH | 1 |
| Banerjee, S | 1 |
| Sengul, G | 1 |
| Takci, E | 1 |
| Malcok, UA | 1 |
| Akar, A | 1 |
| Erdogan, F | 1 |
| Kadioglu, HH | 1 |
| Aydin, IH | 1 |
| Ko, WC | 1 |
| Liu, IM | 2 |
| Chung, HH | 3 |
| Cheng, JT | 3 |
| Su, RB | 2 |
| Wang, WP | 1 |
| Lu, XQ | 1 |
| Wu, N | 1 |
| Liu, ZM | 1 |
| Li, J | 3 |
| Su, CH | 1 |
| Hong, S | 3 |
| Kim, CY | 2 |
| Lee, WS | 1 |
| Shim, J | 1 |
| Yeom, HY | 1 |
| Seong, GJ | 2 |
| Jiang, XZ | 1 |
| Liu, YQ | 1 |
| Zhang, YZ | 1 |
| Zhang, LM | 1 |
| Li, YF | 1 |
| Bahremand, A | 1 |
| Ziai, P | 1 |
| Khodadad, TK | 1 |
| Rahimian, R | 1 |
| Ghasemi, A | 1 |
| Ghasemi, M | 1 |
| Hedayat, T | 1 |
| Ahn, SK | 1 |
| Park, YM | 2 |
| Cowan, A | 1 |
| Lisek, R | 1 |
| Raymondi, N | 1 |
| Rosenthal, A | 1 |
| Hirsch, DD | 1 |
| Rawls, SM | 1 |
| Kim, JH | 2 |
| Lee, YW | 1 |
| Park, SH | 1 |
| Moezi, L | 1 |
| Shafaroodi, H | 1 |
| Hojati, A | 1 |
| Li, JX | 1 |
| Zhang, Y | 1 |
| Winter, JC | 1 |
| Kotagale, NR | 1 |
| Taksande, BG | 1 |
| Wadhwani, PJ | 1 |
| Palhade, MW | 1 |
| Mendhi, SM | 1 |
| Gawande, DY | 1 |
| Hadole, PN | 1 |
| Chopde, CT | 1 |
| Gu, Y | 1 |
| Fan, X | 1 |
| Zhang, C | 1 |
| Yang, X | 1 |
| Bao, YX | 1 |
| Liang, HP | 1 |
| Hara, H | 1 |
| Shimazawa, M | 1 |
| Hyakkoku, K | 1 |
| Al Masri, AA | 1 |
| El Eter, E | 1 |
| Aguiar, AS | 1 |
| Castro, AA | 1 |
| Villarinho, JG | 1 |
| Ferreira, J | 1 |
| Figueiredo, CP | 1 |
| Walz, R | 1 |
| Santos, AR | 6 |
| Tasca, CI | 1 |
| Mar, GY | 1 |
| Chou, MT | 1 |
| Chiu, NH | 1 |
| Chen, MF | 1 |
| Dudkowska, M | 1 |
| Lai, J | 1 |
| Gardini, G | 1 |
| Stachurska, A | 1 |
| Grzelakowska-Sztabert, B | 1 |
| Colombatto, S | 1 |
| Manteuffel-Cymborowska, M | 1 |
| Raasch, W | 1 |
| Jungbluth, B | 1 |
| Schäfer, U | 1 |
| Häuser, W | 1 |
| Dominiak, P | 1 |
| Wei, XL | 1 |
| Liu, Y | 1 |
| Yu, CG | 2 |
| Fairbanks, CA | 2 |
| Wilcox, GL | 2 |
| Yezierski, RP | 2 |
| Yenari, MA | 1 |
| Giffard, RG | 1 |
| Cho, SW | 1 |
| Dias Elpo Zomkowski, A | 1 |
| Oscar Rosa, A | 1 |
| Lin, J | 2 |
| Calixto, JB | 3 |
| Lúcia Severo Rodrigues, A | 1 |
| Zomkowski, AD | 3 |
| Feng, Y | 1 |
| LeBlanc, MH | 1 |
| Regunathan, S | 1 |
| Berenholz, L | 1 |
| Segal, S | 1 |
| Gilad, VH | 2 |
| Klein, C | 1 |
| Yehezkeli, E | 1 |
| Eviatar, E | 1 |
| Kessler, A | 1 |
| Gilad, GM | 2 |
| Kim, DI | 1 |
| Suh, SH | 1 |
| Lee, YJ | 1 |
| Chung, TS | 1 |
| Kotil, K | 1 |
| Kuscuoglu, U | 1 |
| Kirali, M | 1 |
| Uzun, H | 1 |
| Akçetin, M | 1 |
| Bilge, T | 1 |
| Horvath, G | 1 |
| Kekesi, G | 1 |
| Tuboly, G | 1 |
| Benedek, G | 1 |
| Paszcuk, AF | 1 |
| Gadotti, VM | 1 |
| Tibola, D | 1 |
| Quintão, NL | 1 |
| Marc, RE | 1 |
| Jones, BW | 1 |
| Anderson, JR | 1 |
| Kinard, K | 1 |
| Marshak, DW | 1 |
| Wilson, JH | 1 |
| Wensel, T | 1 |
| Lucas, RJ | 1 |
| Kuo, JR | 1 |
| Lo, CJ | 1 |
| Chio, CC | 1 |
| Chang, CP | 1 |
| Lin, MT | 1 |
| Lewis, B | 1 |
| Wellmann, KA | 1 |
| Barron, S | 1 |
| Song, DW | 1 |
| Xing, WX | 1 |
| Jia, LS | 1 |
| Krass, M | 1 |
| Wegener, G | 1 |
| Vasar, E | 1 |
| Volke, V | 1 |
| Salame, K | 1 |
| Rabey, JM | 1 |
| Marcillo, AE | 1 |
| Hammes, L | 1 |
1 review available for agmatine and Disease Models, Animal
| Article | Year |
|---|---|
Aliphatic polyamines in physiology and diseases.
Topics: Agmatine; Animals; Disease Models, Animal; Humans; Neoplasms; Ornithine; Putrescine; Spermidine; Spe | 2014 |
1 trial available for agmatine and Disease Models, Animal
| Article | Year |
|---|---|
Neuroprotective effects of agmatine in experimental peripheral nerve injury in rats: a prospective randomized and placebo-controlled trial.
Topics: Agmatine; Animals; Disease Models, Animal; Male; Neuroprotective Agents; Nitric Oxide Synthase Type | 2014 |
72 other studies available for agmatine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio.
Topics: Agmatine; Animals; Atherosclerosis; Biomarkers; Cholesterol, HDL; Diet, Western; Disease Models, Ani | 2021 |
Agmatine improves olfactory and cognitive deficits in Spontaneously Hypertensive Rats (SHR): An animal model of Attention Deficit Hyperactivity Disorder (ADHD).
Topics: Adult; Agmatine; Animals; Attention Deficit Disorder with Hyperactivity; Cognition; Cognitive Dysfun | 2022 |
Effect of Agmatine on a mouse model of allergic airway inflammation: A comparative study.
Topics: Agmatine; Animals; Anti-Asthmatic Agents; Beclomethasone; Cytokines; Disease Models, Animal; Inflamm | 2022 |
Agmatine relieves behavioral impairments in Fragile X mice model.
Topics: Agmatine; Animals; Calcium Carbonate; Disease Models, Animal; Fragile X Mental Retardation Protein; | 2022 |
Agmatine improves liver function, balance performance, and neuronal damage in a hepatic encephalopathy induced by bile duct ligation.
Topics: Agmatine; Animals; Bile Ducts; Disease Models, Animal; Hepatic Encephalopathy; Rats; Rats, Wistar | 2023 |
Antidepressant-like effects of agmatine and NOS inhibitors in chronic unpredictable mild stress model of depression in rats: The involvement of NLRP inflammasomes.
Topics: Agmatine; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Inflammasomes; Male; N | 2019 |
Agmatine ameliorates manifestation of depression-like behavior and hippocampal neuroinflammation in mouse model of Alzheimer's disease.
Topics: Agmatine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Depression; Disease Models, Animal; Hip | 2020 |
Neuroprotective action of agmatine in rotenone-induced model of Parkinson's disease: Role of BDNF/cREB and ERK pathway.
Topics: Agmatine; Animals; Apoptosis; Brain; Brain-Derived Neurotrophic Factor; Cell Survival; Corpus Striat | 2020 |
Involvement of hippocampal agmatine in β
Topics: Agmatine; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Behavior, Animal; Brain-Derived | 2020 |
Effects of Agmatine on Contrast-Induced Nephropathy in Rats and Rabbits.
Topics: Acute Kidney Injury; Agmatine; Animals; Contrast Media; Disease Models, Animal; Dose-Response Relati | 2020 |
Agmatine has beneficial effect on harmaline-induced essential tremor in rat.
Topics: Agmatine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Essential Tremor; Harm | 2021 |
The inhibition of inducible nitric oxide synthase and oxidative stress by agmatine attenuates vascular dysfunction in rat acute endotoxemic model.
Topics: Agmatine; Animals; Antioxidants; Disease Models, Animal; Down-Regulation; Endothelium, Vascular; End | 2017 |
Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone.
Topics: Agmatine; Anhedonia; Animals; Antidepressive Agents; Cell Proliferation; Corticosterone; Depressive | 2018 |
Agmatine attenuates intestinal ischemia and reperfusion injury by reducing oxidative stress and inflammatory reaction in rats.
Topics: Agmatine; Animals; Carbachol; Disease Models, Animal; Inflammation; Intestine, Small; Male; Malondia | 2017 |
Modulation of the anticonvulsant effect of swim stress by agmatine.
Topics: Agmatine; Analgesics, Opioid; Animals; Anticonvulsants; Arginine; Disease Models, Animal; Dose-Respo | 2018 |
Agmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in rats.
Topics: Agmatine; Analgesics; Animals; Animals, Newborn; Behavior, Animal; Cells, Cultured; Cisplatin; Disea | 2018 |
Agmatine attenuates depressive-like behavior and hippocampal oxidative stress following amyloid β (Aβ1-40) administration in mice.
Topics: Agmatine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Antioxidants; De | 2018 |
Neuroprotective effect of agmatine (decarboxylated l-arginine) against oxidative stress and neuroinflammation in rotenone model of Parkinson's disease.
Topics: Agmatine; Animals; Cytokines; Disease Models, Animal; Glial Fibrillary Acidic Protein; Glutathione; | 2019 |
Functional and pharmacological analysis of agmatine administration in different cerebral ischemia animal models.
Topics: Agmatine; Animals; Brain; Brain Ischemia; Carotid Artery, Common; Disease Models, Animal; Gerbillina | 2019 |
Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation.
Topics: Adaptation, Physiological; Agmatine; Animals; Anti-Bacterial Agents; Cystic Fibrosis; Disease Models | 2019 |
Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration.
Topics: Agmatine; Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; | 2014 |
Agmatine attenuates silica-induced pulmonary fibrosis.
Topics: Agmatine; Animals; Biomarkers; Bronchoalveolar Lavage Fluid; Cytoprotection; Disease Models, Animal; | 2014 |
Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model.
Topics: Agmatine; Alzheimer Disease; Animals; Cognition Disorders; Disease Models, Animal; Male; Rats; Strep | 2014 |
Effects of agmatine on blood-brain barrier stabilization assessed by permeability MRI in a rat model of transient cerebral ischemia.
Topics: Agmatine; Animals; Blood-Brain Barrier; Capillary Permeability; Disease Models, Animal; Infarction, | 2015 |
The arginine decarboxylase pathways of host and pathogen interact to impact inflammatory pathways in the lung.
Topics: Agmatine; Animals; Biofilms; Carboxy-Lyases; Chromatography, High Pressure Liquid; Disease Models, A | 2014 |
The Anti-inflammatory Effects of Agmatine on Transient Focal Cerebral Ischemia in Diabetic Rats.
Topics: Agmatine; Animals; Blotting, Western; Brain; Diabetes Mellitus, Experimental; Disease Models, Animal | 2016 |
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice.
Topics: Agmatine; Animals; Anti-Infective Agents, Local; Antiviral Agents; Cell Survival; Cervix Uteri; Chlo | 2016 |
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors.
Topics: Agmatine; Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Do | 2016 |
Evaluation of the protective effect of agmatine against cisplatin nephrotoxicity with 99mTc-DMSA renal scintigraphy and cystatin-C.
Topics: Acute Kidney Injury; Agmatine; Animals; Cisplatin; Cystatin C; Disease Models, Animal; Female; Kidne | 2016 |
Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism.
Topics: Agmatine; Animals; Autism Spectrum Disorder; Disease Models, Animal; Grooming; Hippocampus; Hyperkin | 2017 |
A preliminary histopathological study of the effect of agmatine on diffuse brain injury in rats.
Topics: Agmatine; Animals; Axons; Brain; Brain Injuries; Cerebrovascular Circulation; Disease Models, Animal | 2008 |
Activation of I(2)-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats.
Topics: Agmatine; Analysis of Variance; Animals; Area Under Curve; Behavior, Animal; Blood Glucose; Blood Pr | 2008 |
Agmatine blocks acquisition and re-acquisition of intravenous morphine self-administration in rats.
Topics: Agmatine; Animals; Disease Models, Animal; Extinction, Psychological; Infusions, Intravenous; Male; | 2009 |
Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats.
Topics: Adrenalectomy; Agmatine; Analysis of Variance; Animals; beta-Endorphin; Blood Glucose; Diabetes Mell | 2009 |
Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model.
Topics: Administration, Topical; Agmatine; Animals; Antihypertensive Agents; Cell Count; Chronic Disease; Di | 2010 |
[Neonatal fluoxetine exposure induced depression-like behaviors in adult Kunming mice and the antidepressant-like effect of agmatine].
Topics: Agmatine; Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Female; Fluox | 2009 |
Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: Involvement of L-arginine/nitric oxide pathway.
Topics: Agmatine; Analysis of Variance; Animals; Antidepressive Agents; Arginine; Disease Models, Animal; Do | 2010 |
Effects of agmatine on hypoxic microglia and activity of nitric oxide synthase.
Topics: Agmatine; Analysis of Variance; Animals; Calcium-Binding Proteins; Cell Hypoxia; Cell Line, Transfor | 2011 |
Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Agmatine; Analysis of | 2011 |
Agmatine-reduced collagen scar area accompanied with surface righting reflex recovery after complete transection spinal cord injury.
Topics: Agmatine; Animals; Bone Morphogenetic Protein 7; Cicatrix; Collagen; Disease Models, Animal; Immunoh | 2011 |
The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice.
Topics: Agmatine; Analysis of Variance; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Rela | 2011 |
Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I₂ receptor ligands.
Topics: Adrenergic alpha-2 Receptor Antagonists; Agmatine; Analgesics; Analgesics, Opioid; Animals; Benzofur | 2011 |
Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents.
Topics: Agmatine; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Disease Mo | 2012 |
[The protective effects of agmatine in zymosan induced acute lung injury in mice].
Topics: Acute Lung Injury; Agmatine; Animals; Disease Models, Animal; Inflammation; Interleukin-6; Lung; Mal | 2011 |
Retinal protective effects of topically administered agmatine on ischemic ocular injury caused by transient occlusion of the ophthalmic artery.
Topics: Agmatine; Animals; Arterial Occlusive Diseases; Disease Models, Animal; Ischemia; Male; Mice; Neurop | 2012 |
Agmatine induces gastric protection against ischemic injury by reducing vascular permeability in rats.
Topics: Agmatine; Androstadienes; Angiopoietin-1; Angiopoietin-2; Animals; Capillary Permeability; Chemokine | 2012 |
Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Agmatine; Analysis of Vari | 2012 |
Changes of imidazoline receptors in spontaneously hypertensive rats.
Topics: Agmatine; Animals; Antihypertensive Agents; Aorta, Thoracic; Benzofurans; Blood Pressure; Blotting, | 2013 |
Agmatine modulates the in vivo biosynthesis and interconversion of polyamines and cell proliferation.
Topics: Acetyltransferases; Agmatine; Animals; Cell Division; Disease Models, Animal; DNA Replication; Epith | 2003 |
Modification of noradrenaline release in pithed spontaneously hypertensive rats by I1-binding sites in addition to alpha2-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Agmatine; Animals; Antihypertensive Agents; Benzofurans; Binding Sites | 2003 |
Antimalarial effect of agmatine on Plasmodium berghei K173 strain.
Topics: Agmatine; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Eflornithine | 2003 |
Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats.
Topics: Agmatine; Animals; Cyclosporine; Disease Models, Animal; Excitatory Amino Acid Agonists; Grooming; I | 2003 |
Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury.
Topics: Agmatine; Analysis of Variance; Animals; Animals, Newborn; Blotting, Western; Brain Infarction; Cell | 2004 |
Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test.
Topics: Agmatine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Diseas | 2004 |
Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test.
Topics: Agmatine; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Female; Male; Mice; Mo | 2005 |
Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects.
Topics: Agmatine; Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Interac | 2005 |
Agmatine treatment and vein graft reconstruction enhance recovery after experimental facial nerve injury.
Topics: Agmatine; Analysis of Variance; Animals; Disease Models, Animal; Electric Stimulation; Facial Nerve | 2005 |
Protective effect of agmatine on a reperfusion model after transient cerebral ischemia: Temporal evolution on perfusion MR imaging and histopathologic findings.
Topics: Agmatine; Animals; Cats; Cerebrovascular Circulation; Disease Models, Animal; Ischemic Attack, Trans | 2006 |
Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial.
Topics: Agmatine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Laminectomy; Lipid Pero | 2006 |
Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice.
Topics: Agmatine; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Female; Imipramine; Im | 2006 |
Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level.
Topics: Adenosine; Agmatine; Analgesics; Animals; Area Under Curve; Disease Models, Animal; Drug Combination | 2007 |
Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice.
Topics: Agmatine; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Cytokines; Disease Models, An | 2007 |
Neural reprogramming in retinal degeneration.
Topics: Agmatine; Amacrine Cells; Animals; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred | 2007 |
Resuscitation from experimental traumatic brain injury by agmatine therapy.
Topics: Agmatine; Animals; Brain Injuries; Disease Models, Animal; Glutamic Acid; Hippocampus; Infusions, Pa | 2007 |
Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure.
Topics: Agmatine; Alcoholism; Animals; Animals, Newborn; Area Under Curve; Body Weight; Central Nervous Syst | 2007 |
[Concentration of endogenous agmatine in normal and injured spinal cord: experiment with rats].
Topics: Agmatine; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Nitric Oxide Syntha | 2007 |
Antidepressant-like effect of agmatine is not mediated by serotonin.
Topics: Agmatine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Diseas | 2008 |
Agmatine treatment is neuroprotective in rodent brain injury models.
Topics: Agmatine; Animals; Brain Injuries; Brain Ischemia; Cells, Cultured; Disease Models, Animal; Gerbilli | 1996 |
Agmatine improves locomotor function and reduces tissue damage following spinal cord injury.
Topics: Agmatine; Animals; Disease Models, Animal; Female; Gait Disorders, Neurologic; Myelitis; Nerve Degen | 2000 |
Agmatine produces antidepressant-like effects in two models of depression in mice.
Topics: Agmatine; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Disease Mode | 2002 |